Luis Puig

30.9k citations
714 papers · 23k · 9 hit papers · h-index 64

Impact in

  • Immunology top 0.05%
    • Psoriasis: Treatment and Pathogenesis
    • Biosimilars and Bioanalytical Methods
  • Dermatology top 0.05%
    • Dermatology and Skin Diseases
    • Hidradenitis Suppurativa and Treatments

Papers in

    • Psoriasis: Treatment and Pathogenesis 382
    • Biosimilars and Bioanalytical Methods 24
    • Dermatology and Skin Diseases 56
    • Contact Dermatitis and Allergies 19

Luis Puig

677 papers receiving 22.2k citations

Luis Puig's Hit Papers

Prevalence of most common skin diseases in Europe: a population‐based study 2022 · 136 citations
1360+4+8Years since publication5001k1.5k

Peers

Luis Puig
Comparison fields: 5 of 146
  • Immunology 12.2k
  • Dermatology 3.7k
  • Rheumatology 3.1k
  • Family Practice 104
  • Epidemiology 1.1k
Replace Kristian Reich with:
Kristian Reich Germany
Alan Menter United States
Catherine Smith United Kingdom
Ulrich Mrowietz Germany
Carle F. Paul France
Alice Bendix Gottlieb United States
Kim Alexander Papp Canada
Richard G B Langley Canada
Peter C.M. van de Kerkhof Netherlands
Kenneth B. Gordon United States
Luis Puig relative to Kristian Reich Germany Kristian Reich's profile →
Citations per field
00.5×1.5×
Kristian Reich · 1×
Citations per year

Countries citing papers authored by Luis Puig

Since Specialization
Citations

This map shows the geographic impact of Luis Puig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Puig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Puig more than expected).

Fields of papers citing papers by Luis Puig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Puig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Puig. The network helps show where Luis Puig may publish in the future.

Co-authors

The 25 scholars most cited alongside Luis Puig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Luis Puig Line = papers co-authored together Luis Puig links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 714 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
Hit paper breakdown →
20141674
2
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Hit paper breakdown →
2015711
3
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Hit paper breakdown →
2013677
4
Epidemiology of atopic dermatitis in adults: Results from an international survey
Hit paper breakdown →
2018668
5 2010596
6
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Hit paper breakdown →
2014560
7
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
Hit paper breakdown →
2018538
8
Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey
Hit paper breakdown →
2014449
9
Development and validation of the International Hidradenitis Suppurativa Severity Score System ( IHS 4), a novel dynamic scoring system to assess HS severity
Hit paper breakdown →
2017381
10 2017337
11 2017283
12 2019275
13 2017251
14 2014248
15 2020233
16 2016230
17 2018203
18 2014198
19 2011189
20 2018175

About Luis Puig

Luis Puig is a scholar working on Immunology, Dermatology, Rheumatology, Pharmacology and Epidemiology, having authored 714 papers that have together received 23k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (382 papers), Dermatology and Skin Diseases (56 papers), Spondyloarthritis Studies and Treatments (41 papers), Biosimilars and Bioanalytical Methods (24 papers), Contact Dermatitis and Allergies (19 papers), Genetic and rare skin diseases. (19 papers), Drug-Induced Adverse Reactions (18 papers) and Vascular Malformations and Hemangiomas (16 papers). The work is most often cited by research in Immunology (12.2k citations), Dermatology (3.7k citations), Rheumatology (3.1k citations), Family Practice (104 citations) and Epidemiology (1.1k citations). Luis Puig has collaborated with scholars based in Spain, United States and Germany. Frequent co-authors include María Teresa Fernández‐Figueras, Giampiero Girolomoni, Mark Lebwohl, Kristian Reich, Agustín Alomar, Richard G B Langley, Tiago Torres, Carlos Ferrándiz, Arthur Kavanaugh and J.M. de Moragas. Their work appears in journals such as Journal of the European Academy of Dermatology and Venereology, British Journal of Dermatology, Journal of the American Academy of Dermatology, Dermatology and Therapy and Journal of Dermatological Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact